Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Aminoglycosides are widely used for the treatment of Gram-negative bacilli and Staphylococcus
aureus infections because of their effectiveness and low cost. Nevertheless, many aspects of
their optimal use in hemodialysis patients remain unsolved and little is known about their
pharmacokinetics in this context. The current practice for prescribing aminoglycosides to
these particular patients consists in giving after each hemodialysis session about half the
dose usually given to patients with normal renal function.
However, theoretical considerations and emerging clinical data suggest that this may not be
the most beneficial dosing regimen as efficient peak concentrations are often not attained
and the occurrence of ototoxicity and nephrotoxicity is still frequent.